<- Go Home
Nuvo Pharmaceuticals Inc.
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada. As of March 14, 2023, Nuvo Pharmaceuticals Inc. operates as a subsidiary of Searchlight Pharma Inc.
Market Cap
CAD 15.4M
Volume
6.0K
Cash and Equivalents
CAD 31.3M
EBITDA
CAD 19.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CAD 45.1M
Profit Margin
62.22%
52 Week High
CAD 1.55
52 Week Low
CAD 0.50
Dividend
N/A
Price / Book Value
1.81
Price / Earnings
4.70
Price / Tangible Book Value
-0.24
Enterprise Value
CAD 83.0M
Enterprise Value / EBITDA
4.29
Operating Income
CAD 12.3M
Return on Equity
1180.47%
Return on Assets
5.85
Cash and Short Term Investments
CAD 31.3M
Debt
CAD 98.9M
Equity
CAD 8.5M
Revenue
CAD 72.4M
Unlevered FCF
CAD 16.5M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium